Limits...
CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.


© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016850&req=5

Mentions: Our systematic literature search of CD147 and its correlation with different outcomes identified 910 articles. Among these, 836 articles were excluded and only 82 studies satisfied the inclusion eligibility for the meta-analysis. Upon further review of the full text articles, eight additional articles from reference sources were included. An additional 29 studies were excluded due to the following reasons: two articles were reviews; three were duplicate reports; four had insufficient data; four included only a few cases; nine explored the prognostic value of CD147/EMMPRIN in combination with other biomarkers, such as VEGF, MMP-2, CD44s, MCT-1; and seven studies were determined to be too complicated for subgroup analysis. The remaining 53 studies567910111213141516171920212223242526272829303132333435363738394041424344454647484950515253545556575859 containing 68 datasets that met our inclusion criteria were included in this review (Fig. 2). Among the eligible studies, 33 provided survival information about the correlation of CD147/EMMPRIN expression with tumor prognosis using a multivariate model and 20 presented the same information using a univariate model. The characteristics of these two models are summarized in Tables 1 and 2, respectively.


CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016850&req=5

Mentions: Our systematic literature search of CD147 and its correlation with different outcomes identified 910 articles. Among these, 836 articles were excluded and only 82 studies satisfied the inclusion eligibility for the meta-analysis. Upon further review of the full text articles, eight additional articles from reference sources were included. An additional 29 studies were excluded due to the following reasons: two articles were reviews; three were duplicate reports; four had insufficient data; four included only a few cases; nine explored the prognostic value of CD147/EMMPRIN in combination with other biomarkers, such as VEGF, MMP-2, CD44s, MCT-1; and seven studies were determined to be too complicated for subgroup analysis. The remaining 53 studies567910111213141516171920212223242526272829303132333435363738394041424344454647484950515253545556575859 containing 68 datasets that met our inclusion criteria were included in this review (Fig. 2). Among the eligible studies, 33 provided survival information about the correlation of CD147/EMMPRIN expression with tumor prognosis using a multivariate model and 20 presented the same information using a univariate model. The characteristics of these two models are summarized in Tables 1 and 2, respectively.

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.